IQVIA offers an attractively priced franchise with a perfect four-quarter earnings beat streak and exceptional free cash flow conversion, but a confirmed technical breakdown and negative price momentum mean fundamental quality and chart reality are in direct conflict, warranting patience before adding exposure.
Thesis pillars
- Perfect Earnings Beat Streak→Stable
- Attractive Valuation Low Peg→Stable
- Superior Free Cash Conversion→Stable
- +1 more pillar — see the Why tab for full reasoning
IQVIA Holdings, Inc. (IQV) Stock Analysis
Range Bound setup
Healthcare · Diagnostics & Research
Wait for pullback to $188.62. At $208.05 the A.R:R is 0.0:1 — below the 1.5:1 minimum for BUY_NOW. Engine's entry $188.62 (support + ATR) is the shallowest technical level that clears the 2:1 A.R:R minimum. Key risks: Analyst target reached - limited upside remaining; Leverage penalty (D/E 2.5): -1.5.
IQVIA provides clinical research services, commercial insights, and healthcare intelligence to life sciences companies through three business segments — Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions — serving over... Read more
Wait for pullback to $188.62. At $208.05 the A.R:R is 0.0:1 — below the 1.5:1 minimum for BUY_NOW. Engine's entry $188.62 (support + ATR) is the shallowest technical level that clears the 2:1 A.R:R minimum. Key risks: Analyst target reached - limited upside remaining; Leverage penalty (D/E 2.5): -1.5. Chart setup: RSI 53 mid-range, Bollinger mid-band. Earnings in 3 days. Wait until post-earnings. Score 5.7/10, moderate confidence.
Passes 5/9 gates (positive momentum, clean insider activity, news events none recent, semi cycle peak clear, materials cycle peak clear). Fails on favorable risk/reward ratio and earnings proximity 3d<=7d. Suitability: moderate.
Recent developments
updated 2026-07-26Recent Developments — IQVIA Holdings, Inc.
Latest news
- NEWS A Look At IQVIA Holdings (IQV) Valuation After ESOP Linked Shelf Registration For Potential Share Issuance - Yahoo Finan — Yahoo Finance neutral
- NEWS IQVIA Holdings (IQV) Earnings Expected to Grow: Should You Buy? - Yahoo Finance — Yahoo Finance positive
- NEWS Vanguard Group Inc. Acquires 159,899 Shares of IQVIA Holdings Inc. $IQV - MarketBeat — MarketBeat positive
- NEWS IQVIA Holdings (IQV) Reports Next Week: Wall Street Expects Earnings Growth - Yahoo Finance — Yahoo Finance positive
- NEWS IQVIA Holdings Inc. 2026 Q1 - Results - Earnings Call Presentation (NYSE:IQV) 2026-05-05 - Seeking Alpha — Seeking Alpha neutral
Generated 2026-07-26T08:02:04Z.
Upcoming dated catalysts
Thesis
Key Metrics
Quality Signals
Options Flow
Material Events(8-K, last 90d)
- 2026-04-23Item 5.02LOWStockholders approved the 2026 Incentive and Stock Award Plan at the April 23, 2026 Annual Meeting. Plan replaces the 2017 Incentive and Stock Award Plan; authorizes stock options, RSUs, restricted stock awards, and performance-based RSUs based on Committee-selected metrics.SEC filing →
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results.
Show full disclosure ▾Hide full disclosure ▴
About TrendMatrix. TrendMatrix is a publisher of general securities research and market commentary. We publish on a regular schedule. All content is the same for every subscriber in a tier — we do not provide personalized investment advice and we do not take into account any individual subscriber's financial situation, investment objectives, risk tolerance, tax situation, or holdings.
Not investment advice. TrendMatrix is not a registered investment adviser. Our content is for informational and educational purposes only. Consult your own licensed investment adviser, broker, or tax professional before making any investment decision.
Conflicts and positions. The TrendMatrix editorial team frequently holds personal long-term positions in securities discussed. We disclose positions held at the time of publication on each piece. We maintain a trading-window policy: we do not initiate or close positions in the same direction as a TrendMatrix publication within 24 hours before or 72 hours after publication.
No paid promotion. TrendMatrix does not accept payment from any issuer, broker, or third party in exchange for coverage of any security. Our sole compensation is subscription revenue.
No fiduciary duty. No fiduciary, advisory, or agency relationship is created between you and TrendMatrix by reading our content or subscribing to our service.
Performance. Past performance is not indicative of future results. Performance figures reflect the published model only and do not reflect any individual subscriber's actual results.
Rating Breakdown
10 dimensions · all in-band
Price Targets
Position Sizing
Risk Alerts
Earnings
Verdict History
Frequently Asked Questions
Wait for pullback to $188.62. At $208.05 the A.R:R is 0.0:1 — below the 1.5:1 minimum for BUY_NOW. Engine's entry $188.62 (support + ATR) is the shallowest technical level that clears the 2:1 A.R:R minimum. Key risks: Analyst target reached - limited upside remaining; Leverage penalty (D/E 2.5): -1.5. Chart setup: RSI 53 mid-range, Bollinger mid-band. Earnings in 3 days. Wait until post-earnings. Target $208.80 (+0.4%), stop $179.87 (−15.7%), A.R:R 0.0:1. Score 5.7/10, moderate confidence.
Take-profit target: $208.80 (+0.4% upside). Target $208.80 (+0.4%), stop $179.87 (−15.7%), A.R:R 0.0:1. Stop-loss: $179.87.
Analyst target reached - limited upside remaining; Leverage penalty (D/E 2.5): -1.5.
IQVIA Holdings, Inc. trades at a P/E of 25.8 (forward 14.7). TrendMatrix value score: 6.4/10. Verdict: Buy (Wait for Entry).
29 analysts cover IQV with a consensus score of 4.0/5. Average price target: $232.
What does IQVIA Holdings, Inc. do?IQVIA provides clinical research services, commercial insights, and healthcare intelligence to life sciences companies...
IQVIA provides clinical research services, commercial insights, and healthcare intelligence to life sciences companies through three business segments — Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions — serving over 10,000 clients in more than 100 countries, including nearly all top 100 global pharmaceutical companies, with approximately 93,000 employees worldwide.